FCRL5 is not only continuously expressed in malignant plasma cells (PCs) of patients,20 but also promotes B-cell proliferation and isotype expression after exposure to the antigen.21–23 Moreover, FCRL5-targeted antibody-drug conjugates are proven to be effective in treating MM.19,20 Therefore, FCRL5 is a potential target for CAR-T MM therapy. The gene discussed is FCRL5; the disease is Miyoshi myopathy.